Xiaozhang Zheng
Overview
Explore the profile of Xiaozhang Zheng including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
351
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ericsson A, Richard D, Wilker E, Lancia Jr D, Fessler S, Troccolo P, et al.
Exp Hematol
. 2024 Nov;
141():104673.
PMID: 39549740
Anemia in patients with sickle cell disease (SCD) increases 2,3-diphosphoglycerate (2,3-DPG), decreasing hemoglobin-oxygen (HbO) affinity to improve oxygen offloading and promote hemoglobin polymerization (sickling) of red blood cells (RBCs). We...
2.
Zheng X, Ji N, Campbell V, Slavin A, Zhu X, Chen D, et al.
J Med Chem
. 2024 Aug;
67(20):18022-18037.
PMID: 39151120
Interleukin-1 receptor associated kinase 4 (IRAK4) is an essential mediator of the IL-1R and TLR signaling pathways, both of which have been implicated in multiple autoimmune conditions. Hence, blocking the...
3.
Weiss M, Zheng X, Ji N, Browne C, Campbell V, Chen D, et al.
J Med Chem
. 2024 Jun;
67(13):10548-10566.
PMID: 38920289
Developing therapies for the activated B-cell like (ABC) subtype of diffuse large B-cell lymphomas (DLBCL) remains an area of unmet medical need. A subset of ABC DLBCL tumors is driven...
4.
Ackerman L, Acloque G, Bacchelli S, Schwartz H, Feinstein B, La Stella P, et al.
Nat Med
. 2023 Nov;
29(12):3127-3136.
PMID: 37957373
Toll-like receptor-driven and interleukin-1 (IL-1) receptor-driven inflammation mediated by IL-1 receptor-associated kinase 4 (IRAK4) is involved in the pathophysiology of hidradenitis suppurativa (HS) and atopic dermatitis (AD). KT-474 (SAR444656), an...
5.
Bora-Singhal N, Mohankumar D, Saha B, Colin C, Lee J, Martin M, et al.
Sci Rep
. 2020 Mar;
10(1):4722.
PMID: 32170113
Non-small cell lung cancer (NSCLC) is known to have poor patient outcomes due to development of resistance to chemotherapy agents and the EGFR inhibitors, which results in recurrence of highly...
6.
Yue L, Sharma V, Horvat N, Akuffo A, Beatty M, Murdun C, et al.
Blood
. 2019 Nov;
135(3):191-207.
PMID: 31750881
Protein acetylation is an important contributor to cancer initiation. Histone deacetylase 6 (HDAC6) controls JAK2 translation and protein stability and has been implicated in JAK2-driven diseases best exemplified by myeloproliferative...
7.
Follows B, Fessler S, Baumeister T, Campbell A, Zablocki M, Li H, et al.
Bioorg Med Chem Lett
. 2019 Jun;
29(16):2375-2382.
PMID: 31235261
Mcl-1 is an anti-apoptotic protein overexpressed in hematological malignancies and several human solid tumors. Small molecule inhibition of Mcl-1 would offer an effective therapy to Mcl-1 mediated resistance. Subsequently, it...
8.
Martin M, Lee J, Lancia Jr D, Ng P, Han B, Thomason J, et al.
Bioorg Med Chem Lett
. 2018 May;
28(12):2143-2147.
PMID: 29776742
N-Hydroxy-2-arylisoindoline-4-carboxamides are potent and selective inhibitors of HDAC11. The discovery, synthesis, and structure activity relationships of this novel series of inhibitors are reported. An advanced analog (FT895) displays promising cellular...
9.
Kerres N, Steurer S, Schlager S, Bader G, Berger H, Caligiuri M, et al.
Cell Rep
. 2017 Sep;
20(12):2860-2875.
PMID: 28930682
The transcription factor BCL6 is a known driver of oncogenesis in lymphoid malignancies, including diffuse large B cell lymphoma (DLBCL). Disruption of its interaction with transcriptional repressors interferes with the...
10.
Zak M, Yuen P, Liu X, Patel S, Sampath D, Oeh J, et al.
J Med Chem
. 2016 Aug;
59(18):8345-68.
PMID: 27541271
NAMPT inhibitors may show potential as therapeutics for oncology. Throughout our NAMPT inhibitor program, we found that exposed pyridines or related heterocyclic systems in the left-hand portion of the inhibitors...